Cilta-Cel Continues to Show Durable Efficacy in Multiple Myeloma
The CAR T-cell therapy elicited an overall response rate (ORR) of 97.9% at a median follow-up of 18 months.
The Importance of Donor Resources: Gregory S. Hageman, PhD
The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed the 8,000 donated eye repository that aided his research in AMD.
High Incidence of C Difficile Following Allogeneic Stem Cell Transplant
Patients with CDI also had more severe acute graft vs. host disease than those without CDI.
Unmet Needs With Car T Therapy in Multiple Myeloma: Nina Shah, MD
The hematologist and oncologist from the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center discussed unmet needs with CAR T-cell therapy in multiple myeloma.
State of Cell Therapy in Multiple Myeloma: Nina Shah, MD
The hematologist and oncologist from University of California, San Francisco discussed the current state of cellular therapy in multiple myeloma.
MD Anderson to Offer Solutions to Cell Therapy AEs
The new technologies were made available as a result of the licensing agreement between MD Anderson and Bellicum Pharmaceuticals.
OpRegen Continues to Show Efficacy in Dry AMD Geographic Atrophy
Lineage Cell Therapeutics announced promising data from interim results of the phase 1/2a clinical trial assessing the cell therapy.
Updated KarMMA Data of Ide-Cel in Multiple Myeloma: Larry D. Anderson Jr, MD, PhD
The associate professor from the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center discussed the latest data from the KarMMA trial.
GeneTherapyLive’s Weekly Rewind – September 17, 2021
Review top news and interview highlights from the week ending September 17, 2021.
Cell Therapy for Critical Limb Ischemia Shows Positive Interim Data
An interim analysis has met prespecified safety and efficacy checkpoints.
BET Proteins and T-Cell Function: Joseph A. Fraietta, PhD
The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed his research into the mechanisms of the BET protein family and T cells.
Challenging Paradigms in AMD: Gregory S. Hageman, PhD
The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed his team’s research in the role of HTRA1.
Improving Safety With CAR Engager Proteins
Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s research on CAR T therapies.
Cell Therapy for AML Granted Fast Track Designation
A phase 1/2a clinical trial assessing VOR33 is currently enrolling.
Gene-Independent Therapeutic Strategies for Retinal Degeneration
Researchers are exploring gene-independent therapeutic strategies to circumvent the challenges of gene-replacement therapies.
Expanding the Use of CAR T Therapy With shRNA
The chief executive and chief medical officers of Celyad Oncology discussed the company’s future research and plans.
Astellas Pauses Gene Therapy Trial for X-Linked Myotubular Myopathy
Following a voluntary pause, a patient experiencing a liver AE has died and the trial is now on clinical hold.
T Cell Therapy Trial for High-Risk Patients With COVID-19 Now Enrolling
TVGN-489 is an investigational allogeneic cytotoxic CD8+ T lymphocyte therapy that may help prevent breakthrough COVID infection.
Optimizing Manufacturing of NK Cell and CAR T Therapies for Cancer Treatment
Jan Davidson, MD, PhD, chief medical officer, Wugen, discussed the company’s cell therapy platforms.
New Collaboration to Develop Gene Therapy for Chronic Retinal Diseases
RGX-314 is being developed to target wet AMD, diabetic retinopathy, and other chronic retinal diseases.
Integrating CAR T Therapy in Multiple Myeloma: Krina K. Patel, MD, MSc
The associate professor from The University of Texas MD Anderson Cancer Center discussed the integration of CAR T-cell therapy into the treatment paradigm of R/R MM.
Bone Therapeutics Shifts Focus to Cell Therapies Following Phase 3 Fail in Knee Osteoarthritis
The company is currently evaluating ALLOB, its investigational cell therapy product for bone regeneration.
CAR T-Cell Utility in Hematologic Cancers: Alex Herrera, MD
The hematologist and oncologist from City of Hope discussed the utility of CAR T cells in patients with hematologic cancers.
TAC T-Cell Therapy vs CAR T-Cell Therapy
Paul Lammers, MD, MSc, president and chief executive officer, Triumvira Immunologics, discussed the company’s T-cell antigen coupler technology.
TIL Adoptive Cell Therapy for the Treatment of mNSC Lung Cancer
A new TIL therapy seeks to improve on current treatments for metastatic non-small cell lung cancer such as PD-1 inhibitors.
Addressing Exhausted T-Cells in CAR T Therapy: Joseph A. Fraietta, PhD
The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed the issue of exhausted T-cells.
AAV-Based Gene Therapy for Autoimmune Uveitis
A single-dose gene therapy for uveitis could fill an important treatment gap for patients.
Developing Natural Killer Cell Therapies for Hematologic Malignancies and Solid Tumors
The chief executive and medical officers of Cytovia Therapeutics discussed their natural killer cell therapy technology.
Gene Therapy for Congenital Hearing Loss Granted Orphan Drug, Rare Pediatric Disease Designations
Decibel Therapeutics previously presented favorable preclinical data at ASGCT 2021.
RNA-Modified vs DNA-Modified CAR T Products
Michael Singer, MD, PhD, chief scientific officer, Cartesian Therapeutics, discussed the company’s RNA Armory technology.
